Mylan Launches Gilead Sciences' Sovaldi Tablets in India

Loading...
Loading...
Mylan N.V.
MYL
today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched Gilead Sciences'
GILD
Sovaldi (sofosbuvir 400mg tablets) in India. Sovaldi is indicated for the treatment of chronic hepatitis C infection, a blood-borne infectious disease, as a component of a combination antiviral treatment regimen. It is estimated that approximately 12 million people are chronically infected with hepatitis C in India.
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...